Clinical Research Awards are offered to provide support for investigator-initiated clinical research projects that have the potential to make an important contribution to the Cystic Fibrosis Foundation’s mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of cystic fibrosis using clinical (observational/interventional), translational, or epidemiologic study approaches. Applicants must demonstrate access to sufficient numbers of CF patients and appropriate controls. Applicants interested in the Multiple-PI option should contact the Program Officer, Dara Riva, at driva@cff.org.
Up to $150,000 per year (plus 12% indirect costs) for a maximum of three years may be requested for single-center clinical research awards.
For multi-center clinical research, the potential award is up to $350,000 per year (plus 12% for indirect costs) for a maximum of three years.
Up to an additional $100,000 over the entire project period may be available via supplemental funding.
*NEW* Supplemental Funding to Address High Priority Areas
Remote Collection Supplement: Applicants may request an additional $50,000 (plus 12% indirect costs) over the entire project period to include an additional aim that leverages the proposed main research study aims that address important gaps in knowledge and improve our understanding of the utility of remote collection of either specimens, endpoints, and/or clinical data to address these gaps in knowledge. This supplement is not intended to support Quality Improvement research in sample collection or patient use of daily therapies.
Health Equity Supplement: Applicants may request an additional $50,000 (plus 12% indirect costs) over the entire project period to either advance our knowledge of health disparities in cystic fibrosis or enhance the diversity, equity, and inclusion in the biomedical workforce.
Spring 2024
- Letter of Intent: September 21, 2023
- Full application: February 13, 2024
Fall 2024
- Letter of Intent: April 4, 2024
- Full application: August 13, 2024